Two series of thiazolidinone derivatives designing for potential EGFR and HER-2 kinase inhibitors have been discovered. Some of them exhibited significant EGFR and HER-2 inhibitory activity. Compound 2-(2-(5-bromo-2-hydroxybenzylidene) hydrazinyl) thiazol-4 (5H)-one (12) displayed the most potent inhibitory activity (IC50= 0.09 μM for EGFR and IC50= 0.42 μM for HER-2), comparable to the positive control erlotinib. Docking simulation ...